Related Experiment Video
Updated: May 28, 2026

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
Prevalence of potential drug-drug interactions in bone marrow transplant patients
Rosimeire Barbosa Fonseca Guastaldi1, Adriano Max Moreira Reis, Albert Figueras
1Instituto do Coração, Hospital das Clínicas, University of São Paulo, São Paulo, Brazil.
Objective:
To assess the prevalence of potential drug-drug interactions (DDIs) in bone marrow transplantation (BMT) patients at the time of pre-infusion (day -1), to describe the potential DDIs and assess their frequency and severity.
Setting:
The study was developed in a tertiary care hospital in São Paulo, Brazil.
Method:
Cross-sectional study based on examining the medical prescriptions from the pre-infusion day (day -1) of 70 BMT patients. Potential DDIs were analyzed using Drug-Reax(®) and categorized according to levels of severity, evidence, and onset (rapid and delayed). Only interactions of major or moderate severity were included in the potential DDI analysis.
Main Outcome Measure:
Prevalence of potential DDIs in patients during the preinfusion phase of BMT.
Results:
Data were analysed for 70 BMT patients. The median age was 36.5 years; 52.9% (37) of the patients were male, and 65.7% (46) were undergoing autologous BMT. The patients received a median of 8 drugs each. Up to 128 potential DDIs were detected, 60.0% (42) of patients had at least 1 potential DDI and 21.4% (15) were exposed to at least 1 major potential DDI. The most commonly involved drugs were cyclosporine (9, 28.1%), phenytoin (8, 25%) and fluconazole (5, 15.6%). Most potential DDIs had moderate severity (110, 85.9%), a pharmacokinetic mechanism (67, 52.3%), and were classified as delayed onset (106, 82.8%). For major interactions, fluconazole + sulfamethoxazole/trimethoprim, diazepam + fentanyl, fluconazole + levofloxacin and fentanyl + fluconazole were the most frequent.
Conclusions:
The prevalence of potential DDIs during the conditioning period of BMT was high as a consequence of the therapeutic complexity of the procedure. Most potential DDIs identified in the study may result in clinically relevant consequences as they could lead to nephrotoxicity, cardiotoxicity, and other undesirable adverse effects. Careful monitoring of clinical and laboratory parameters is essential to ensure a successful BMT and to avoid adverse drug events related to DDI.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Drug toxicity: Drug–Drug Interaction
Pharmacokinetics: Drug–Drug Interactions
Drug Toxicity: Risk factors
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...

